AJMC October 23, 2024
Laura Joszt, MA

Kimberly Westrich, MA, of National Pharmaceutical Council, and Adam Colborn, JD, of AMCP, run through the current status of lawsuits and lawmaking at the federal and state levels related to pharmacy benefit managers and cost-shifting programs.

At the latest AMCP Nexus meeting, Kimberly Westrich, MA, chief strategy officer, National Pharmaceutical Council, and Adam Colborn, JD, associate vice president of Congressional Affairs, AMCP, discussed legislation and lawsuits at the state and federal level that could impact patients costs for drugs.

Colborn discussed legislation related to pharmacy benefit managers (PBMs), while Westrich discussed cost-shifting programs, such as co-pay accumulators and maximizers and alternative funding programs.

According to Colborn, while there is a lot of attention on PBMs at the federal level, the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article